TGFB1 and Myocardial fibrosis: ARNI like sacubitril/valsartan can inhibit myocardial remodeling by inhibiting RAAS and neprilysin, inhibit the expression of chromogranin A (CgA) to inhibit ventricular remodeling, and reduce myocardial fibrosis by inhibiting TGF-β expression [84].